v3.26.3
Consolidated Statements of Income (Loss) - USD ($)
shares in Millions, $ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Income Statement [Abstract]        
Net revenues $ 4,395 $ 4,480 $ 12,519 $ 12,547
Cost of sales 1,955 2,176 5,954 6,264
Gross profit 2,440 2,304 6,565 6,282
Research and development expenses 297 256 1,489 746
Selling and marketing expenses 709 656 2,122 1,933
General and administrative expenses 298 317 919 920
Intangible assets impairments 24 64 54 227
Other assets impairments, restructuring and other items 264 62 438 272
Legal settlements and loss contingencies 202 60 504 312
Other loss (income) (68) 7 (96) 15
Operating income (loss) 714 882 1,135 1,857
Financial expenses, net 414 237 854 714
Income (loss) before income taxes 300 646 282 1,143
Income taxes (benefit) 66 214 254 210
Share in (profits) losses of associated companies, net [1] (2) [1] (4)
Net income (loss) 234 434 27 937
Net income (loss) attributable to redeemable and non-redeemable non-controlling interests 1 1 1 7
Net income (loss) attributable to Teva $ 233 $ 433 $ 26 $ 930
Earnings (loss) per share attributable to ordinary shareholders:        
Basic (in dollars per share) $ 0.20 $ 0.38 $ 0.02 $ 0.81
Diluted (in dollars per share) $ 0.20 $ 0.37 $ 0.02 $ 0.80
Weighted average number of shares (in millions):        
Basic (in shares) 1,166 1,147 1,162 1,144
Diluted (in shares) 1,183 1,164 1,180 1,160
[1]
Represents an amount less than $0.5 million.